posit time covid
upgrad ew ow valuat pipelin
option maintain ow rate
downgrad bhc ow ew due earn
risk high leverag revis industry-wid estim
major pharmaceut framework continu see industri rel
resili view major pharma rel attract given defens
qualiti compani continu solid financi prospect despit
impact due offer attract dividend yield capit
ew ow given attract valuat pipelin option ow-rat
offer durabl growth least depend new launch ow-
rate merck valuat appear attract consid new sotp analysi
impli core pharma busi ex-vaccin anim health trade
ep see exhibit although expect exit either
vaccin anim health think analysi elucid attract
valuat remain ew although valuat appear attract
await spin-rel financi adjust note ibranc adjuv trial
uncertainti rate pt chang
specialti pharma/anim shift equal-weight bausch
elanco given consum exposur high leverag recess risk signific
per ms economist cheytan ahya march report full-court polici press
march report deeper recess depress
downgrad bausch overweight equal-weight due compani
vision dermatolog approx compani sale exposur
recess slower de-lever less transact option
downgrad elanco overweight equal-weight
concern sale downsid could mute compani margin expans stori
coronaviru challeng could affect speed bayer synergi captur
project higher financi leverag lower pro forma ebitda key
overweight-r stock specialti pharma remain given
strong sale prospect tepezza thyroid eye diseas even though
tepezza krystexxa sale temper
see opportun biopharma execut capit
industri role power life-sav forc tremend nation asset
polit public sentiment toward pharma pivot critic
high drug price construct industri potenti address
coronaviru threat reduc legisl threat washington offici
champion develop novel drug vaccin
industri immun market downturn reduc financi project
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
price target industry-wid expect disrupt revenu cost clinic
trial fda action major pharma compani resili
lower revenu rang
ep rang specialti pharma
compani estim chang includ wider rang note exclud amneal
recent complet acquisit revenu
ep exhibit
exhibit
biopharma outperform broader equiti market earli dot-
com crash global financi crisi recess
biopharma better rel price perform ntm rel net incom
compar broader market exhibit exhibit ms chief
context perform valuat net incom rel valuat chart
addit note histor us prescript trend resili
coronaviru uniqu rx trend histor recess resist covid
unpreced section
comprehens report follow new invest these bristol upgrad
ow bausch bhc downgrad ew elanco downgrad ew
updat risk-reward stock coverag histor rx trend
recess resist covid unpreced us drug launch could
impact social distanc anim health compani sale perform
financi crisi fx implic
act financi advisor merck co merck connect
intent spin-off product women legaci brand
biosimilar franchis new yet-to-be-nam independ publicly-trad
compani announc februari transact subject market
certain condit merck agre pay fee
financi servic includ fee conting upon consumm
transact pleas refer note end report
 co llc affili co intern
plc act financi advis inc
relat propos offer acquir allergan plc allergan announc
june propos transact effect mean scheme
arrang chapter part compani act subject
regulatori approv customari close condit report
inform provid herein intend provid vote advic ii serv
endors propos transact iii result procur
withhold revoc proxi action secur holder
agre pay fee financi servic includ
transact fee conting upon consumm propos
transact pleas refer note end report
tabl content
rate pt chang
upgrad ow
bhc downgrad ew
downgrad ew
rx trend histor recess resist covid unpreced
 drug launch could impact social distanc
recess impact anim health
rate pt chang
pt
valuat base stand-alone estim
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
exhibit merck sotp analysi suggest current price under-valued estim profit
margin multipl vaccin anim health solv impli pharma margin
adjust project across univers stock coverag reflect
impact project modest neg impact major pharmaceut greater
impact specialti pharma anim health
incorpor follow model
revenu upsid due pull-forward demand human pharmaceut
downsid consum work extra rx social distanc drive
higher cog due expect rise suppli cost includ materi input
lower sg due reduc commerci spend physician visit confer etc
lower due trial delay confer cancel travel restrict etc
caveat compani provid guidanc updat swing factor could
greater impact updat model reflect
exhibit revenu estim revis see footnot
amneal estim increas due acquisit avkar jan number stand-alone estim number reflect total compani elanco estim assum bayer anim health acquisit
exhibit ebitda estim revis see footnot
amneal estim increas due acquisit avkar jan number stand-alone estim number reflect total compani elanco estim assum bayer anim health acquisit
exhibit ep estim revis see footnot
amneal estim increas due acquisit avkar jan number stand-alone estim number reflect total compani elanco estim assum bayer anim health acquisit
upgrad ow
upgrad ew ow pt
upgrad bristol myer equal-weight overweight due attract
valuat pipelin option chang pt old ep
new ep thesi
pipelin debat valuat offer limit upsid given long-term gener
eros risk new thesi stock pullback present opportun given
rel good earn visibl pandem see posit
pipelin readout ahead catalyst note d/ev highest
among major pharma exhibit pipelin expect could rise time
pt base upon ep pt multipl discount
peer mean one standard deviat histor
mean forward pe believ multipl justifi
see potenti strong perform despit covid disrupt given long
term eros risk pt multipl slightli certain larg cap
compani similarli challeng long term growth outlooksi
alexion cover matthew harrison trade ep note
offer higher dividend yield
fundament develop watch near-term ozanimod zeposia approv
multipl sclerosi better-than-expect label first dose monitor
requir launch temporarili delay due pandem
expect next ozanimod catalyst positivephas ulcer coliti uc
result north would support ozanimod first
sphingosin indic uc well novel oral option biolog
inject addit expect encourag phase data readout bms-
psoriasi late
expect offer better benefit-risk ratio jak inhibitor also
potenti crohn lupu phase readout come year third bristol factor
xia phase readout stroke axiomatic-ssp vte axiomatic-
offer option final bristol robust hematology-oncolog
pipelin driver multipl myeloma liquid tumor ahead
could wrong coronavirus-rel disrupt could wors
expect financi result could disappoint delay new drug launch clinic
trial could longer anticip pipelin readout could fall short
exhibit d/ev us eu major pharma
bhc downgrad ew
downgrad bausch overweight equal-weight due consum exposur
vision dermatolog higher leverag chang pt
old ebitda new ebitda prior thesi
bausch would benefit acceler growth financi de-lever
plu share could benefit transact option downgrad stock
due compani vision dermatolog approx compani sale
exposur recess slower de-lever less transact option posit
balanc factor certain high-qual franchis potenti under-valued
debt paydown time could benefit equiti valu financi market rebound
could boost share lower revenu
ebitda increas net debt ebitda
see balanc risk-reward wide bull-bear rang due
compani equiti valu repres enterpris valu exhibit
bhc high beta stock sensit stock market perform bausch
pt base ev/ ebitda pt multipl in-lin spec
phrma mean one standard deviat bhc histor
mean forward ev/ebitda believ multipl justifi
see near-term growth uncertainti balanc low valuat bhc consum
franchis set face pressur recess bhc highest net debt
 ebitda among peer balanc core bausch lomb brand strength
low valuat bhc stock price ytd largest
fundament develop watch sale perform particularli consumer-
orient franchis vision dermatolog dental growth product
xifaxan updat plan launch sihi daili us late debt market
trend implic potenti debt refinanc come year note
bhc need refin debt near-term could
opportunist elect refin rate attract develop watch
includ xifaxan-rel patent litig potenti canadian stock drop litig
could ew rate wrong share could outperform due stock market
pressur financi upsid potenti strateg transact share could
under-perform due stock market downsid pressur high beta stock
financi disappoint neg news relat product xifaxan sale
downgrad ew
downgrad elanco overweight equal-weight due earn risk higher
leverag depend upon bayer merger integr chang pt
pro forma old ep pro forma new ep
prior thesi base strong ep growth prospect potenti margin upsid
earlier/larg project cost save attract valuat
downgrad stock concern sale downsid could mute
compani margin expans stori coronaviru challeng could affect speed
bayer synergi captur anticip higher financi leverag lower pro forma
ebitda lower pro forma revenu
ebitda increas net debt ebitda
exhibit see balanc risk-reward pleas see risk reward
pt base upon pro forma ep pt multipl discount
ep one standard deviat
histor mean forward price-to-earnings project double-digit pro forma
ep growth believ multipl justifi see strong long-term
growth potenti despit near term covid disrupt recess face
greater risk cost synergi margin expans depend
bayer transact speed integr delay due covid
note anim health stock coverag withdrawn
fundament develop watch growth trend companion anim
livestock bayer anim health merger updat model complet juli
competit develop impact simparica trio gener
rumensin sale elanco competitor pipelin updat
could wrong share could outperform due coronaviru impact
less fear financi upsid posit pipelin updat share could
under-perform due coronaviru impact wors anticip financi
downsid addit competit entri anoth tripl combo paraciticid
exhibit new vs old estim elanco-bay pro forma- incl bayer ah acquisit juli
elanco ipo came
rx trend histor recess resist covid
rx spike due covid
pull-forward human rx refil demand set impact
result human pharma compani experi upsid follow
downsid prescript data major pharma rx chart rx spike due covid
autoimmun drug moder indic hoard rx refil march much
pull forward like revers april social distanc suggest less physician
visit thu fewer new rx start rais major pharma revenue ep
lower revenue ep
exhibit total market weekli yoy growth note spike march due rx refil
hoard could revers april
histor prescript trend indic rx resili prior
us prescript trend recess pandem resist ran iqvia
histor rx trend data start see impact recess
histor event crisi pandem
observ moder still posit yoy growth sever month
recess pandem start follow higher yoy growth later exhibit note
increas use prescript contribut factor lower
observ compar adjust prescript length
exhibit iqvia us total market absolut yoy trend sinc note increas use prescript drove yoy
declin adjust growth year posit see exhibit follow yellow line
adjust length therapi
exhibit trx continu increas yoy adjust prescript length
iqvia report medicin use spend
 drug launch could impact disrupt
exhibit product expect launch coverag univers
launch expect
parasit prevent dogs/puppi
cellulit buttock
ed cataplexi narcolepsi
ret nsclc thyroid cancer
simparica trio sale total simparica franchis sale lynparza sale allianc revenu estim report
launch expect later
total
exhibit new drug approv juli date pace sale ramp could impact impact commerci
patient visit
imipenem cilastatin relebactam
astrazeneca daiichi sankyo
fda gov morgan stanley research approv data march
estim fx impact global revenu major pharma
calcul averag fx impact global revenu full year
major pharma compani rel usd stronger euro
exhibit in-lin yen exhibit simpl fx explan
weaker usd benefit ex-u sale respect region stronger usd yoy
impact ex-u sale neg respect region
exhibit estim fx impact total top-lin base upon spot rate
exhibit estim fx impact revenu base upon spot rate
fx impact global revenu spec pharma
exhibit estim fx impact total top-lin base upon spot rate
exhibit estim fx impact revenu base upon spot rate
recess impact anim health quantifi
revenu trend period follow
pfizer anim health subsidiari zoeti cc cc
n/a note close acquisit wyeth octob
bayer cc cc
lilli elanco grew cc cc perform
help acquisit posilac close octob
merck growth skew due organon acquisit schere
novemb sale declin cc n/a note merck close
acquisit schere plough novemb
breakout companion anim vs livestock sale note
mani small us farmer went bankrupt impact livestock perform
would differ social distanc relat
sever reduc vet visit global start march mani pet
owner refil exist pet prescript rate vaccin new
prescript start gap second quarter recess could
limit overal companion anim demand global recess also like
impact livestock demand difficult estim magnitud impact lower
consum incom anim protein consumpt
exhibit histor anim health revenu yoy growth
schere acquir organon bioscienc novemb later got acquir bump revenu acquir wyeth
octob led increas revenu acquir posilac octob mention constant currenc cc
growth year avail toher year mark avail na
opdivo yervoy chemo
opdivo yervoy chemo
pdufa low intermedi risk rs myelodysplast syndrom medalist
roch tecentriq nsclc final os readout rel pt
updat data r/r multipl myeloma phase karmma phase
pdufa dlbcl base submit dec
pdufa r/r multipl myeloma karmma submit
phase adjuv melanoma all-com fail popul
phase psoriasi
phase anemia ntd beta-thalassemia beyond top-line result
opdivo cisplatin erbitux radiotherapi phase adjuv cancer
opdivo yervoy chemo
opdivo yervoy chemo
opdivo yervoy chemo
long-term follow data bristol competitor bcma molecul r/r multipl myeloma
pivot trial data r/r cll
 bcma car-t r/r multipl myeloma cartitud prim compl sept
phase induct crohn diseas prim compl
phase transfusion-depend myelofibrosi associ anemia independ plan initi
full data disclosur fail dian-tu trial aat-ad/pd focu virtual meet
aducanumab -amyloid antibodi file decis fda
pdfua egfr nsclc file
pdufa nsclc thyroid cancer
w/ abcellera biolog co-develo antibodi therapeut treat diseas expect enter clinic trial summer
phase readout gastric/gej cancer prim compl jul
phase top-lin result chronic heart failur reduc ef emperor-reduc prim compl jun
phase readout roch semorinemab anti-tau prodromal-earli alzheim tauriel prim endpt/compl cdr-sb jun
tri-agonist phase data diabet prim/studi compl sep
basal insulin-fc weekli
novo ozemp phase combo cilofexor firsocostat nash readout prim compl may
pdufa high dose
phase readout diabet prim compl oct
phase dementia prim compl oct
phase cll/sll prim compl oct
pdufa non-radiograph axial spondyloarthr file late
pdufa type type diabet file late
data high dose trial posit top-line
data compet bimekizumab ucb phase trial psoriasi vivid stelara comp readi sure humira comp toplin octdec
patent litig rule us alt salt form rule favor lilli apotex sinc file appeal
phase data licens chugai primary/studi compl apr
phase data diabet prim/studi compl feb
phase diabet
w/ nektar phase data eczema psoriasi prim/studi compl jan
outcom teva suit alleg patent infring mass district court litig stay pend resolut ipr ptab rule patent
favor teva favor lilli
phase ulcer coliti induct readout prim compl sept said like delay due
phase readout chronic heart failur preserv ef emperor-preserv prim compl oct
phase earli alzheim readout prim endpt iadr trailblazer-alz prim compl dec
phase readout diabet vs tresiba prim compl dec
phase readout diabet inadequet control lantu prim compl jan
phase alopecia areata readout prim compl dec
phase readout diabet vs trulic surpass j-mono prim compl apr
phase readout diabet vs ozemp add-on metformin prim compl
phase readout diabet vs lantu prim compl may
oral phase readout type diabet prim compl apr
phase readout roch semorinemab anti-tau moder alzheim lauriet prim endpt/compl adcs-adl may
phase earli alzheim readout prim endpt iadr prim compl aug
fda action atop dermat submiss expect
phase atop dermat adher feb prim compl jun prim compl jun
phase solid tumor prim compl dec
phase readout diabet without sulfonylurea surpass-ap-combo prim compl feb
phase readout obes prim compl feb
phase readout nash synergy-nash prim compl
phase high dose earli alzheim readout prim compl jul studi vs previous fail phase trial
phase readout chronic kidney diseas empa-kidney prim compl jun
ret-fus nsclc ret-mut thyroid cancer prim compl dec feb respect
phase readout vs trulic diabet cv diseas surpass-cvot plan initi
keytruda chemo radiotherapi
adult pediatr
keytruda chemo radiotherapi
readout prevnar -- efficaci implic percept
roch tecentriq non-squam nsclc final os readout rel prim compl
keytruda phase readout cutan squam cell carcinoma prim compl dec
beigen phase tislelizumab chemo vs chemo metastat squamou nsclc china detail
data present posit interim
phase readout nasopharyang cancer prim compl march
phase data roch tecentriq tiragolumab tigit combo
phase readout tyvyt innovent/lilli chemo vs chemo metastat non-squam nsclc
china detail data present posit interim
cv outcom trial readout vs placebo verti cv result present ada
phase readout tnbc vs chemo posit detail
present upcom medic meet
phase readout rcc vs sutent prim compl apr
phase readout adjuv mono /neoadjuv chemo tnbc ef data expect
phase readout bladder vs chemo prim compl may
phase readout endometriosi prim compl jun
pfe/merck kgaa phase bavencio vs dose vs chemo nsclc javelin lung
beigen phase tislelizumab chemo vs chemo metastat non-squam nsclc china prim
phase readout tyvyt innovent/lilli chemo vs chemo metastat squamou nsclc
china prim compl aug
phase imfinzi azn crt unresect stage nsclc readout prim compl sept
phase readout treatment-na hiv prim compl oct
phase tecentriq adjuv chemo stage ib-iiia nsclc readout prim compl
interim analysi
phase readout vs xtandi zytiga profound estimate file us eu/jpn
phase readout eight trial expect file
fda action pfizer prevnar adult file expect
phase mcrpc vs zytiga xtandi prim compl oct
phase bispecif merck kgaa/gsk vs keytruda nsclc readout prim
compl oct
phase ilari nv keytruda chemo vs keytruda nsclc
merck phase vs prevnar pediatr trial pneu-link readout compl may
phase readout stage unresect nsclc prim compl dec
phase readout msi-high vs chemo prim compl dec
phase advanc solid tumor prim compl jun
solid tumor mediola readout prim compl aug
phase nsclc
pdufa date april braf-mut mcrc
vaccin collabor updat enter clinic test end april
phase trial readout bla submiss one posit top-line
phase detail data mainten bladder cancer javelin bladder posit top-line
phase readout ankylos spondyl prim compl dec
phase poc topic cream mild-to-moder psoriasi mild-to-moder atop dermat
detail data phase jade atop dermat posit top-line
phase poc addit patient data duchenn muscular dystrophi phase plan
phase anchor braf-mut mcrc anchor-crc readout med conf
phase interim efficaci readout adjuv hr breast cancer palla prim compl sep
phase poc readout prevent respiratori syncyti viru infect phase shortli posit readout
cv outcom trial readout vs placebo verti cv result present ada
phase poc readout prelim result support studi detail releas follow compl data
present major vaccin med conf
phase dupix jade compar ad posit top-lin await detail fill later
phase vs dose vs chemo nsclc javelin lung readout prim compl jun
phase top-lin result high risk relaps neoadjuv breast cancer penelope-b prim compl dec
phase readout non-metastat hormon sensit prostat cancer embark prim compl jul
merck phase vs pneumovax adult trial readout primari studi compl aug
phase readout psoriat arthriti prim compl apr
phase poc readout psoriasi
phase readout vitiligo
phase readout alopecia prim compl sept
pdufa dose moder sever osteoarthr
phase start possibl collabor roch
phase readout cancer pain prim compl aug
phase readout solid tumor javelin parp medley prim compl aug
merck adult pediatr phase readout eight trial
phase readout adjuv hr breast cancer palla prim compl sep
fda action file expect
phase pediatr readout file merck
competitor upadacitinib phase readout atop dermat vs dupix head prim/fin compl jan
phase readout type diabet prim compl apr
phase readout ulcer coliti prim compl dec
phase readout ulcer coliti prim compl dec
merck phase vs prevnar pediatr trial pneu-link readout compl may
phase readout metastat er breast cancer patina prim compl may
phase readout head neck cancer javelin head neck prim compl apr
phase readout adjuv high-risk tripl neg breast cancer a-brav prim compl jun
phase readout ovarian vs chemo avastin javelin ovarain parp prim compl
phase readout lupu prim compl sep
phase readout crohn prim compl
phase readout crohn prim compl
phase readout solid tumor combo javelin medley prim compl dec
phase readout local advanc head neck cancer reach prim/studi compl
quarterli sale result monthli rx trend
tecfidera patent challeng ipr rule favor
biogen/alkerm northern district west virginia vs
judg could rule ms est district delawar vs gx
compani judg could rule ms est
pdufa schizophrenia bipolar disord launch
newsflow updat data artistri ph solid tumor artistri
prim compl sept artistri prim compl
ph data readout prim/studi compl jul
approv launch
pipelin newsflow exp complex product launch next
month updat relat competit top franchis
approv launch
file myasthenia gravi treatment
approv launch
approv launch
uptak launch ramp lumifi duobrii bryhali sihi daili relistor
vyzulta siliq trulanc
quarterli updat cash flow oper de-lever progress
potenti resolut investig litig matter
potenti refinanc transact debt equiti issuanc
us launch expect later
ph overt hepat encephalopathi ohe full result posit interim top-line
initi studi evalu new formul gi
patent infring lawsuit updat potenti gxifaxan threat
vs sandoz file xifaxan
vs norwich receiv parag iv xifaxan
ph small intestin bacteri overgrowth sibo updat enrol expect
begin
ph post-operative crohn updat studi expect start
trifexi credelio interceptor simparica trio us launch exp earli eu canada launch
elanco bayer ah quarterli result updat guidanc
newsflow relat rumensin competit landscap impact due huvepharma
grumensin potenti risk addit gx
updat cost optim initi margin expans progress
african swine fever updat overal econom trend global trade
develop speci market trend cattl especi
quarterli updat cash flow oper de-lever progress
newsflow relat durabl gener threat
nevakar launch steril inject hospit critic care base
xyrem nightli equival
xyrem nightli equival
vs krystexxa ph compar top-line data
ph vs placebo initi
launch ramp perman j-code could assign juli effect
oct
quarterli result incl growth driver xyrem sunosi vyxeo
updat suppli disrupt licens renew pbl current
licens pbl sell product
ph atlanti trial sclc lurbi vs topotecan cav top-line data
pdufa ed cataplexi narcolepsi
fda action date sclc prioriti review grant base
ph acut gvhd top-line data expect
expect initi ph essenti tremor acquir cavion
ph trial ed major depress disord plan
ph lbl readout primari compl interim
analysi pt enrol pt bla earli
sept enrol complet
ph pvod interim analysi first patient
roll launch germani franc uk launch earli
updat avadel open-label switch xyrem trial plan
initi
us gener price trend sale
quarterli result upjohn stand-alone
requir notifi revanc later day
date revanc provid certain deliver
tecfidera patent challeng ipr rule favor biogen/alkerm
northern district west virginia vs judg could rule
ms est district delawar vs gx compani judg could
rule ms est
newco financi guidanc deal close
fda warn letter morgantown facil updat
launch uptak add competitor approv
launch uptak add competitor approv competit sandoz
launch uptak add competitor approv launch earli dec
quarterli earn financi result nutrit specialti vaccin
 activ busi develop
african swine fever updat overal econom trend global trade
develop speci market trend cattl especi
quarterli result vs expect consum segment key driver
rx exit action crystal valuat gener busi
suppli launch ramp
suppli chain updat
 activ busi develop
us gener price trend sale
gener stabil austedo cgrp growth
quarterli updat free cash flow de-lever progress
tourett syndrom ph readout ph trial
complet dec respect
potenti fda action gcopaxon applic amneal synthon biocon
dr reddi
outcom teva suit alleg patent infring mass district court
litig stay pend resolut iprs- ptab rule
patent favor teva favor lilli
launch uptak vs brituxan broader label
launch uptak add competitor approv launch face
competit pressur launch juli biocon/mylan dec
potenti approv launch gx filer includ amneal dr reddi
potenti approv launch
potenti approv launch
quarterli earn apoquel simparica cytopoint sale trend
simparica trio us launch ramp us approv eu laucnh feb
updat relat mab pipelin launch expect cat dog
african swine fever updat overal econom trend global trade
develop speci market trend cattl especi
price
price
price
thomson reuter morgan stanley research estim valuat methodolog risk associ price target referenc research report pleas contact client support follow
us/canada hong kong latin america london singapor sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa
us specialti brand gener
price
price
spec brand gx mean
spec brand gx median
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
exhibit drg btk vs rel price perform drg outperform
certain year typic trade poorli
close price
exhibit drg btk absolut price perform global financi crisi
exhibit best worst perform stock coverag univers sinc mid-februari close
close price
exhibit highli lever compani need delev
exhibit debt larg percentag enterpris valu mani spec pharma compani
market trough
ntm ni rel top rh
market trough
exhibit major pharma price-to-earnings rel last year pharma rel price-to-earnings bounc
recent week remain depress vs histor level
includ
pharma price-to-earnings rel
pt multipl discount peer mean one standard
deviat histor mean forward pe believ
multipl justi see potenti strong perform despit covid
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
due attract valuat pipelin
option see compel potenti
ozanimod broader pipelin
believ market discount
eros key franchis mid-lat decad
revenu compound-annual-growth-rate ep compound-annual-growth-rate
higher/low model
add futur growth driver
view descript risk reward theme
posit pipelin newsow upsid
posit pipelin newsow upsid
succeed drive upsid out-year
estim compel readout factor
stroke/vt prevent revenu
synergi upsid drive ep
engag value-enhanc strateg
attract valuat pipelin option
attract valuat pipelin option
disrupt due celgen acquisit
readout ozanimod ulcer coliti
autoimmun diseas bristol
abl extend heme-onc
leadership addit pipelin driver
pipelin nancial fall short and/or
pipelin nancial fall short and/or
delay trial readout
delay trial readout opdivo cm-
result
concern toxic merger integr
problemat synergi disappoint
downsid revenu synergi yield
ep forecast
quarterli sale earn perform
pipelin newsow includ trial result
regulatori approv opdivo cancer
psoriasi ozanimod ibd heme-onc
china india
view explan region hierarchi
research highest favor quintil
upsid risk nancial result
newsow competitor disappoint
downsid risk nancial shortfal product
risk disappoint strateg action
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
result follow posit top-line
reblozyl pdufa low risk rs myelodysplast
base case ep premium peer averag due lilli better
overweight share base upon
expect upward pressur
long-term consensu ep pipelin
ep compar con revenue
ep
lilli offer higher durabl
growth prospect peer given
potenti margin expans pipelin
transact enhanc long-term growth
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
earn forecast alzheim
surpris upsid growth driver
upsid yield ep forecast
alzheim surpris upsid
investor enthusiasm blockbust
better expect
upward pressur long-term consensu
forecast pipelin progress drive
out-performance see potenti
upward pressur consensu ep due
also contribut modest multipl
consensu
view descript risk reward theme
financi key pipelin agent
competit pressur diabet
expect major clinic trial
becom concern us drug
price impact wors
trulic data high dose trial
posit top-line
antibodi w/ abcellera biolog co-develo
antibodi therapeut treat diseas expect
emgality-outcom mass district court
litig teva cgrp patent
solanezumab full data disclosur fail dian-tu trial
